Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant 500mg as First Line Treatment in HR+ Metastatic Breast Cancer
NCT00585507Phase 2Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Apr 2004
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant in breast cancer, sponsored by Beth Israel Deaconess Medical Center. Started Apr 2004; status: active, not recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00585507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00585507.